Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

492
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
492
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

3
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
3
T Cell Types and Functions01:24

T Cell Types and Functions

959
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
959
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

8
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
8
Atherosclerosis II: Clinical manifestations and prevention01:27

Atherosclerosis II: Clinical manifestations and prevention

2
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
2

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Creating a Trauma-Informed Multidisciplinary Clinic.

Birth (Berkeley, Calif.)·2025
Same author

<i>Letter to the Editor:</i> Response to Dr. Mousavi's Comments on Ogunsola et al.

Cannabis and cannabinoid research·2025
Same author

Metastatic SQSTM1-NTRK1 fused non-small-cell lung cancer treated with larotrectinib and stereotactic radiosurgery resulting in durable complete response: a case report.

Therapeutic advances in medical oncology·2025
Same author

Extracellular vesicles from human-induced pluripotent stem cell-derived neural stem cells alleviate proinflammatory cascades within disease-associated microglia in Alzheimer's disease.

Journal of extracellular vesicles·2024
Same author

Recent Updates on COVID-19 Associated Strokes.

Neuroscience insights·2024
Same author

Intranasally Administered EVs from hiPSC-derived NSCs Alter the Transcriptomic Profile of Activated Microglia and Conserve Brain Function in an Alzheimer's Model.

bioRxiv : the preprint server for biology·2024

Related Experiment Video

Updated: Jun 11, 2025

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

8.9K

Multiple Sclerosis and COVID-19: An Overview on Risk, Severity, and Association With Disease Modifying Therapies.

Mary Hollist1, Abraham Hollist2, Katherine Au3

  • 1Atrium Health, Concord, NC, USA.

Neuroscience Insights
|September 30, 2024
PubMed
Summary

Coronavirus disease 2019 (COVID-19) affects the central nervous system, posing risks for multiple sclerosis (MS) patients. Some MS patients experience neurological symptoms, relapses, or disease severity after COVID-19 infection.

Keywords:
COVID-19SARS-CoV-2disease-modifying therapiesmultiple sclerosis

More Related Videos

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

4.7K
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

57.9K

Related Experiment Videos

Last Updated: Jun 11, 2025

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

8.9K
Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

4.7K
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

57.9K

Area of Science:

  • Neurology
  • Infectious Diseases
  • Immunology

Background:

  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19, a global health crisis initially known as a respiratory illness.
  • Emerging evidence shows COVID-19 significantly impacts the central nervous system.
  • Patients with pre-existing neurological disorders, like multiple sclerosis (MS), are particularly vulnerable.

Purpose of the Study:

  • To review the neurological manifestations of COVID-19.
  • To analyze the impact of COVID-19 on patients with multiple sclerosis (MS), especially those on disease-modifying therapies.
  • To explore the association between MS and SARS-CoV-2, including neuroinvasiveness, pathogenesis, disease severity, and outcomes.

Main Methods:

  • Comprehensive literature review.
  • Analysis of research findings on neurological implications of COVID-19 in MS patients.
  • Examination of factors influencing disease severity and outcomes.

Main Results:

  • COVID-19 can lead to substantial neurological complications in some MS patients.
  • A notable proportion of MS patients with COVID-19 experience new or worsening neurological symptoms.
  • Risk of disease relapse and increased severity are observed in MS patients with COVID-19.

Conclusions:

  • While advancements in management (vaccination, antivirals) have reduced overall COVID-19 impact, MS patients remain at risk.
  • Patients with advanced MS, particularly those on anti-CD20 therapy and with existing disability, face higher risks.
  • Ongoing vigilance and tailored care are crucial for managing COVID-19 in vulnerable MS patient subgroups.